Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Study design and methodology of the PREVAIL trial: a phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of subcutaneous ALXN1720 in adults with generalized myasthenia gravis

              Author:Howard, James   Rakhade, Sanjay   Scholz, Joachim   Ortiz, Stephan   Shang, Shulian   Vu, Tuan   

              Session Name:P1: Autoimmune Neurology: Myasthenia Gravis  

              Topic:Autoimmune Neurology  

              Program Number:P1.008  

              Author Institution:University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC  Alexion, AstraZeneca Rare Disease, Boston, MA  University of South Florida, Tampa, FL  

              Long-term Efficacy and Safety of Symptom-driven Cyclic Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis: A Pooled Analysis of a Phase 3 Study and Two Open-label Extension Studies

              Author:Bril, Vera   Druzdz, Artur   Grosskreutz, Julian   Habib, Ali A.   Mantegazza, Renato   Utsugisawa, Kimiaki   Vissing, John   Vu, Tuan   Boehnlein, Marion   Gayfieva, Maryam   Greve, Bernhard   Woltering, Franz   Kaminski, Henry J.   

              Session Name:P1: Autoimmune Neurology: Myasthenia Gravis  

              Topic:Autoimmune Neurology  

              Program Number:P1.012  

              Author Institution:University Health Network, Toronto, ON, Canada  Municipal Hospital Poznan, Poznan, Poland  University of Lübeck, Lübeck, Germany  University of California, Irvine, Orange, CA  Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy  Hanamaki General Hospital, Hanamaki, Japan  Rigshospitalet, University of Copenhagen, Copenhagen, Denmark  University of South Florida Morsani College of Medicine, Tampa, FL  UCB Pharma, Monheim, Germany, Monheim, Germany  UCB Pharma, Slough, UK, Slough, United Kingdom  UCB Pharma, Monheim, Germany, Monheim , Germany  George Washington University, Washington, DC  

              Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Patients with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study

              Author:Howard, James   Li, George   Vu, Tuan   Korobko, Denis   Smilowski, Marek   Liu, Li   Steeland, Sophie   Noukens, Jan   Van Hoorick, Benjamin   Podhorna, Jana   Li, Yuebing   Utsugisawa, Kimiaki   Sacca, Francesco   Wiendl, Heinz   De Bleecker, Jan   Mantegazza, Renato   ADAPT-SC Investigator Study Group, in collaboration with the   

              Session Name:P1: Autoimmune Neurology: Myasthenia Gravis  

              Topic:Autoimmune Neurology  

              Program Number:P1.014  

              Author Institution:The University of North Carolina, Chapel Hill, NC  Medsol Clinical Research Center Inc, Port Charlotte, FL  University of South Florida, Morsani College of Medicine, Tampa, FL  State Budgetary Healthcare Institution of Novosibirsk Region "State Novosibirsk Regional Clinical Hospital", Novosibirsk, Russian Federation  Medical University of Silesia, Katowice, Poland  argenx, Ghent, Belgium  Curare Consulting BV, Etten-Leur, Netherlands  Cleveland Clinic, Cleveland, OH  Hanamaki General Hospital, Hanamaki, Japan  Federico II University of Naples, Napoli, Italy  University of Münster, Münster, Germany  Ghent University Hospital, Ghent, Belgium  Fondazione Istituto Neurologico Carlo Besta, Milan, Italy  N/A, Yardley, PA  

              Efgartigimod Demonstrates Consistent Improvements in Generalized Myasthenia Gravis Patients of Shorter Disease Duration

              Author:Bril, Vera   Vu, Tuan   Brauer, Edward   Kerstens, René   Howard, James   ADAPT Investigator Study Group, in collaboration with the   

              Session Name:P1: Autoimmune Neurology: Myasthenia Gravis  

              Topic:Autoimmune Neurology  

              Program Number:P1.015  

              Author Institution:Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, Toronto, ON, Canada  University of South Florida, Morsani College of Medicine, Tampa, FL  argenx, Ghent, Belgium  The University of North Carolina, Chapel Hill, NC  N/A, Yardley, PA  

              Dose Selection and Clinical Development of Efgartigimod PH20 Subcutaneous in Patients with Generalized Myasthenia Gravis

              Author:Li, George   Li, Yuebing   Vu, Tuan   Korobko, Denis   Smilowski, Marek   Liu, Li   Steeland, Sophie   Van Hoorick, Benjamin   Podhorna, Jana   Casey, Jenna   Noukens, Jan   Van Bragt, Tonke   Utsugisawa, Kimiaki   Wiendl, Heinz   De Bleecker, Jan   Mantegazza, Renato   Howard, James   ADAPT-SC Investigator Study Group, in collaboration with the   

              Session Name:P1: Autoimmune Neurology: Myasthenia Gravis  

              Topic:Autoimmune Neurology  

              Program Number:P1.017  

              Author Institution:Medsol Clinical Research Center Inc, Port Charlotte, FL  Cleveland Clinic, Cleveland, OH  University of South Florida, Morsani College of Medicine, Tampa, FL  State Budgetary Healthcare Institution of Novosibirsk Region "State Novosibirsk Regional Clinical Hospital", Novosibirsk, Russian Federation  Medical University of Silesia, Katowice, Poland  argenx, Ghent, Belgium  argenx, Afton, MN  Curare Consulting BV, Etten-Leur, Netherlands  Hanamaki General Hospital, Hanamaki, Japan  University of Münster, Münster, Germany  Ghent University Hospital, Ghent, Belgium  Fondazione Istituto Neurologico Carlo Besta, Milan, Italy  The University of North Carolina, Chapel Hill, NC  N/A, Yardley, PA